Treatment of primary degenerative dementia and multi-infarct dementia with glycosaminoglycan polysulfate: A comparison of two diagnoses and two doses

Glycosaminoglycan polysulfate is a mixture of sulfomucopolysaccharides with a standardized composition and reproducible biologic activity. In a 12-week, multicenter clinical trial the therapeutic effects of two dosages—250 lipasemic-releasing units (LRU) per day and 500 LRU/day—of parenterally admin...

Full description

Saved in:
Bibliographic Details
Published inCurrent therapeutic research Vol. 54; no. 1; pp. 44 - 64
Main Authors Conti, L., Cassano, G., Ban, T.A., Fjetland, O.K., Grossi, D., Lazzerini, F., Modafferi, A., Morey, L.C., Placidi, G.F., Postiglione, A., Re, F., Santini, V.
Format Journal Article
LanguageEnglish
Published Belle Mead, NJ EM Inc USA 1993
Excerpta medica
Subjects
Biological and medical sciences
Medical sciences
Miscellaneous
Neuropharmacology
Pharmacology. Drug treatments
Human
Cerebral infarction
Nervous system diseases
Multicenter study
Cardiovascular disease
Posology
Parenteral administration
Cerebral disorder
Vascular disease
Chemotherapy
Treatment
Glycosaminoglycan
Cerebrovascular disease
Comparative study
Dementia
Online AccessGet full text

Cover

More Information
Summary:Glycosaminoglycan polysulfate is a mixture of sulfomucopolysaccharides with a standardized composition and reproducible biologic activity. In a 12-week, multicenter clinical trial the therapeutic effects of two dosages—250 lipasemic-releasing units (LRU) per day and 500 LRU/day—of parenterally administered glycosaminoglycan polysulfate were compared in two diagnostically distinct populations: (1) patients with primary degenerative dementia of the Alzheimer type, and (2) patients with multi-infarct dementia. It was found that there were significant changes from pretreatment to end of therapy with regard to measures of objective performance, psychopathology, and social behavior. Improvement was consistently greater in the group with primary degenerative dementia than in the group with multi-infarct dementia. On the other hand, no consistent differences in therapeutic effects between the two doses could be seen. The drug was well tolerated; side effects were infrequent and mild. No clinically significant laboratory abnormalities were encountered during the 3-month clinical trial.
ISSN:0011-393X
1879-0313
DOI:10.1016/S0011-393X(05)80617-4